The present invention provides crystals of (1R,3R,15E,28R,29R,30R,31R,34R,36R,39S,41R)-29,41-Difluoro-34,39-bis(sulfanyl)-2,33,35,38,40,42-hexaoxa-4,6,9,11,13,18,20,22,25,27-decaaza-34λ.sup.5,39λ.sup.5-diphosphaoctacyclo[28.6.4.1.sup.3,36.1.sup.28,31.0.sup.4,8.0.sup.7,12.0.sup.19,24.0.sup.23,27]dotetraconta-5,7,9,11,15,19,21,23,25-nonaene-34,39-dione (Compound (I)) ammonium salts, Compound (I) sodium salts, or Compound (I), possessing a potential to be used as drug substance in pharmaceuticals. ##STR00001##

The present invention provides crystals of (1R,3R,15E,28R,29R,30R,31R,34R,36R,39S,41R)-29,41-Difluoro-34,39-bis(sulfanyl)-2,33,35,38,40,42-hexaoxa-4,6,9,11,13,18,20,22,25,27-decaaza-34λ.sup.5,39λ.sup.5-diphosphaoctacyclo[28.6.4.1.sup.3,36.1.sup.28,31.0.sup.4,8.0.sup.7,12.0.sup.19,24.0.sup.23,27]dotetraconta-5,7,9,11,15,19,21,23,25-nonaene-34,39-dione (Compound (I)) ammonium salts, Compound (I) sodium salts, or Compound (I), possessing a potential to be used as drug substance in pharmaceuticals. ##STR00001##

A method of cyclizing an L-RNA aptamer by modifying the aptamer with a 3′ azide and a 5′ alkyne group and using click chemistry reaction-based method. The cyclized L-RNA aptamers have improved binding properties and favour more in vitro/cell applications. Also disclosed is an L-oligonucleotide aptamer having linked ends.

The present invention provides compounds of Formula I′:

##STR00001##

wherein

##STR00002##

W, X, Y, Z, Z.sub.1, Z.sub.2, R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are effective at modulating the STING protein and thus can be used as medicaments for treating or preventing disorders affected by the agonism of STING.

The present invention provides compounds of Formula I′:

##STR00001##

wherein

##STR00002##

W, X, Y, Z, Z.sub.1, Z.sub.2, R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are effective at modulating the STING protein and thus can be used as medicaments for treating or preventing disorders affected by the agonism of STING.

The invention provides a polycyclic aromatic compound or a salt thereof having a partial structure represented by the following general formula (I): ##STR00001##
wherein X, ring A, ring B, ring C, and ring D are as defined in the specification.

The invention provides a polycyclic aromatic compound or a salt thereof having a partial structure represented by the following general formula (I): ##STR00001##
wherein X, ring A, ring B, ring C, and ring D are as defined in the specification.

Disclosed are oral care compositions of novel phosphono-phosphate and anionic group containing polymer compositions that have targeted uses with divalent cations and surfaces having divalent cations. These compounds can be used to deliver anionic character to surfaces such as calcium hydroxyapatite for use in oral care applications.

Disclosed are oral care compositions of novel phosphono-phosphate and anionic group containing polymer compositions that have targeted uses with divalent cations and surfaces having divalent cations. These compounds can be used to deliver anionic character to surfaces such as calcium hydroxyapatite for use in oral care applications.

Disclosed are oral care compositions of novel phosphono-phosphate and anionic group containing polymer compositions that have targeted uses with divalent cations and surfaces having divalent cations. These compounds can be used to deliver anionic character to surfaces such as calcium hydroxyapatite for use in oral care applications.